Seegene Inc., a global leader in molecular diagnostics (MDx), is advancing its vision for innovation in laboratory automation with the development of CURECA™ — a next-generation system currently under development, designed to streamline automation in Polymerase Chain Reaction (PCR) testing and laboratory environments.

The company announced that it will showcase a conceptual video introducing the CURECA™ system at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025), held April 11-15 in Vienna, Austria. The video will outline the system’s design goals and envisioned workflow. A physical demonstration of the system is expected to take place in July 2025 at the Association for Diagnostics & Laboratory Medicine (ADLM 2025) in Chicago.

CURECA™ — short for Continuous Unlimited Random access Expandable and Customizable full Automation — is Seegene’s envisioned PCR testing solution, intended to enable full automation of the PCR testing workflow. The system is expected to include two core components: the Customizable Pre-treatment System (CPS), responsible for sample loading and pre-treatment processing; and Customizable and Expandable Full Automation (CEFA), which would carry out sample loading and preparation for nucleic acid extraction, PCR setup, gene amplification, and result analysis.